EUCTR2007-001315-31-CZ
Active, not recruiting
Not Applicable
Double-blind, randomised, placebo-controlled, multi-centre phase III clinical study on the efficacy and tolerability of budesonide capsules versus placebo for maintenance of remission in patients with collagenous colitis - SOIBD Collagenous Colitis Maintenance Study (SCCMS)
DrugsBudenofalk 3 mg
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Dr. Falk Pharma GmbH
- Enrollment
- 110
- Status
- Active, not recruiting
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Patients aged \>\= 18 years,
- •\- Histologically established diagnosis of collagenous colitis (CC) defined as:
- •a) Thickened sub\-epithelial collagen layer \>\= 10 µm on well\-orientated sections
- •b) Increased amount of inflammatory cells indicating chronic inflammation in the
- •lamina propria
- •\- History of non\-bloody, watery diarrhoea for more than 2 weeks prior screening in
- •patients with nexly diagnosed collagenous colitis, or history of clinical relapse for
- •more than 1 week prior screening in patients with previously established
- •collagenous colitis
- •\- A mean of \>\= 3 stools/day, thereof a mean of \>\= 1 watery stolls/day, during the
Exclusion Criteria
- •\- Other significant abnormalities at colonoscopy that may have been the cause
- •of diarrhoea, with the exception of colonic diverticulosis and polyps \< 2 cm
- •\- Infectious cause of diarrhoea
- •\- Untreated active celiac disease
- •\- Clinical suspicion of drug\-induced collagenous colitis
- •\- Any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder
- •\- Abnormal hepatic function (ALT or ALP \> 2\.5 x upper limit of normal ULN), liver
- •cirrhosis, or portal hypertension
- •\- Local intestinal infection
- •\- Radiation therapy towards the abdominal or pelvic region
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Double-blind, randomised, placebo-controlled, multi-centre phase III clinical study on the efficacy and tolerability of budesonide capsules versus placebo for maintenance of remission in patients with collagenous colitis - SOIBD Collagenous Colitis Maintenance Study (SCCMS)Collagenous colitisMedDRA version: 8.1 Level: LLT Classification code 10048928 Term: Colitis collagenousEUCTR2007-001315-31-BEDr. Falk Pharma GmbH92
Active, not recruiting
Not Applicable
Double-blind, randomised, placebo-controlled, multi-centre phase III clinical study on the efficacy and tolerability of budesonide capsules versus placebo for maintenance of remission in patients with collagenous colitis - SOIBD Collagenous Colitis Maintenance Study (SCCMS)Collagenous colitisMedDRA version: 13.1Level: PTClassification code 10048928Term: Colitis collagenousSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2007-001315-31-DKDr. Falk Pharma GmbH110
Active, not recruiting
Not Applicable
Study to compare the combination of ursodeoxycholic acid andbudesonide with the combination of ursodeoxycholic acid and placebo inthe treatment of primary biliary cirrhosisPBC patients with an incomplete response to UDCA treatment defined by the failure to achieve s-AP levels < 1.5x upper limit of normal after at least 6 months of treatment with UDCA and with inflammatory activity in the histological assessment of the liverMedDRA version: 18.0Level: LLTClassification code 10036680Term: Primary biliary cirrhosisSystem Organ Class: 100000004871Therapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2007-004040-70-LTDr. Falk Pharma GmbH144
Active, not recruiting
Not Applicable
Double-blind, randomised, placebo-controlled, multi-centre phase III clinical study on the efficacy and tolerability of budesonide capsules versus placebo for maintenance of remission in patients with collagenous colitis - SOIBD Collagenous Colitis Maintenance Study (SCCMS)Collagenous colitisMedDRA version: 14.1Level: LLTClassification code 10048928Term: Colitis collagenousSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2007-001315-31-DEDr. Falk Pharma GmbH110
Active, not recruiting
Not Applicable
Study to evaluate the effectiveness and safety of 3 doses ofembryonated eggs of the porcine whipworm compared to placebo(dummy drug) in the treatment of active Crohn's disease.Induction of remission in active Crohn´s diseaseMedDRA version: 14.1Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2006-000720-13-DKDr. Falk Pharma GmbH400